COVID-19 Vaccine Safety Interest Group (CVSIG) Meeting Minutes

Date and Time:

Thursday, May 6th, 2021

7 am - 8 am EST

Attendees

Present	Country/ Organization	Name	Present	Country/ Organization	Name
	Brazil	Mario Borges	х	Saudi Arabia	Hind Almodaimegh
х	Canada	David U (temporary)	х	Singapore	Augustine Tee
х	Canada	Dorothy Tscheng		Singapore	Alvin Lee
	Canada	Gary Lee	х	Singapore	Raymond Chua
х	Canada	Gloria Giraldo	х	Singapore	Adelina Young (MOH)
	Colombia	Ismael Basto	х	Singapore	Benjamin Lim (MOH)
	Colombia	Juan Pablo Osorio	х	Singapore	Jiaxue NG
х	European Medicines Agency (EMA)	Alexios Skarlatos	Х	Singapore	Luisa Tan
х	France	Etienne Schmitt	х	Spain	Maria Jose Otero
х	France	Marie-Blanche Rabier	Х	Uppsala Monitoring Centre (UMC)	Alem Zekarias
X	Germany	Birgit Vogt	х	USA	Christina Michalek
	Germany	Torsten Hoppe-Tichy	х	USA	Jill Paslier
	Health Canada	Jhona Rose	х	USA	Merissa Andersen
х	Health Canada	Sally Pepper	х	USA	Mike Cohen
	Hong Kong	Benjamin Lee	х	USA	Rita Jew
	International Society of Pharmacovigilance (ISoP)	Angela Caro		USA	Andrew Furman
х	International Society of Pharmacovigilance (ISoP)	Brian Edwards	х	USA	Matthew Fried
	Ireland	Muriel Pate	х	USA	David Yoon
х	Ireland	Niamh O'Hanlon		US Food and Drug Administration (FDA)	Lubna Merchant
	Medicines and Healthcare products Regulatory Agency (MHRA) UK	Mitul Jadeja		US Food and Drug Administration (FDA)	Karen Farizo
х	Morocco	Ghita Benabdallah		US Food and Drug Administration (FDA)	Craig Zinderman
х	Morocco	Houda Sefiani		United Arab Emirates (UAE)	Sohail Fitieh
	National Health Service (NHS) UK	Jennie Hall		Vaccine Dynamics USA	John Grabenstein
х			х	World Health Organization	
	Netherlands	Jacob (Jaap) Dik	.,	(WHO)	Ayako Fukushima
	Netherlands	Rob Essink	X		Aaron Soh
х	New Zealand	Michael Tatley	Х		Jalene Poh
	Norway	Sigurd Hortemo	х		Norah BinSabbar
			х		Syafiq
			Х		De Tian (MOH)

Topic Presenter Discussion Action Items

Welcome	Chris Michalek	Introduction Recap from last time: heard from Norway, Canada, Sweden and ISMP fellows	None
Member Presentations- New Zealand	Dr. Michael Tatley Director New Zealand Pharmacovigilance Centre, University of Otago	NZ Vaccine Safety Surveillance Strategy - Passive monitoring - CIR monitoring - CARM - Reports are triaged (review for serious reports) - Independent safety monitoring board - Active monitoring - Adverse events - Hospital surveillance - Mortality review group 300k doses. 3,300 adverse events. 0.8% reporting rate. CARM to receive reports resulting in HARM.	None
Member Presentations- Singapore	Dr. Alvin Lee Deputy Director of Professional Training and Assessment Standards at the Ministry of Health	#iGotMyShot hashtag Scheduling and screening Challenges: - Administer vaccine to contraindicated group (e.g., pregnant women, immunocompromised patients) - Booking second dose too early/late Interventions - Registration app screens people who are not eligible - Book both doses at the same time - On day of vaccination- another screening for eligibility Vaccine preparation Challenges - Compromised cold chain - Incorrect volume of diluent, or undiluted vaccine - Expired vaccines - Mix-ups of similar vials (Moderna COVID-19 vial and Regeneron monoclonal antibody) Interventions - 1 venue only holds 1 vaccine (staff only needs to know one, decrease prep errors). Visual guides to help distinguish between two vaccines - SMS alert alerts 3 people if vaccine refrigerator deviates from range. Backup power supply plan required - Prefilled syringes must be stored with corresponding vials - First in/first out system for retrieving vials from refrigerator - Vials labeled with date and time of dilution and expiration date Handover checklist when handing over duties (date/time of dilution, dilution status, pre-admin verification of patient and vaccine) - Physically separate are for dilution and administration - Limit distractions for vaccine preparation and administration. No multitasking, staff has adequate rest time Staff to check vial and syringe for discoloration or particulates Staff to check 5 rights.	None
		Challenges - Need to have competent, trained, qualified vaccinators	

Significant manpower needed-training new vaccinators				
- Immune system disorders, nervous system disorders, cardiovascular disorders, respiratory disorders, skin disorders Member Presentations- Saudi Almodaimegh Chairperson Saudi Medication Safety Center Plan to cover next time	Presentations-	Benabdallah Poison Control and Pharmacovigilance	- Training toolkit, and competency assessment - End-to-end guidance for vaccination providers - Ground communication and feedback (site inspections, incident reports, ops instructions) SAE and incident management Challenges: - Licensing requirements for handling medical emergencies. Interventions - All patients must stay 30 minutes after vaccination for observation - MOH's guidance on management of anaphylaxis and severe allergic reactions - If patient experiences symptoms after leaving vaccination site- protocol for if/when they visit any clinic or hospital - Must submit incident report to MOH within 3 hours (no need to establish causality) - Serious AE: 0.004% Vaccination record - Vaccination card - Trace together app - Health hub (personal record) AEFI surveillance system - Collecting data, validation and data analysis, database alimentation, signal detection and validation, risk quantification alert generation, RCA and risk minimization actions Vaccination strategy involving PV - Obligatory AE reporting. Organizing monitoring of AEFI at regional and national level. Reporting - Phone call, use app, visit doctor → reported to national pharmacovigilance center Vaccination plan - AZ and Sinopharm - Primary group 75+, healthcare providers 40+, teachers 45+, police/firemen 40+ - Contraindications: pregnancy/breastfeeding, previous anaphylaxis or angioedema, active ongoing disease	None
Presentations- Saudi Arabia Chairperson Saudi Medication Safety Center Almodaimegh Chairperson Saudi Medication Safety			 Immune system disorders, nervous system disorders, cardiovascular disorders, respiratory disorders, skin 	
Next Steps Chris Michalek Next Meeting	Presentations-	Almodaimegh Chairperson Saudi Medication Safety	Plan to cover next time	
	Next Steps	Chris Michalek	Next Meeting	

		 Two more country presentations Presentation about INN names Working meeting to identify top concerns and recommendations Considering booster vaccinations 	
Respectfully submitted, Jill Paslier, PharmD, CSP, ISMP International Medication Safety Management Fellow			